David Rageot

539 total citations
18 papers, 398 citations indexed

About

David Rageot is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Rageot has authored 18 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Rageot's work include Genetic factors in colorectal cancer (4 papers), Renal Transplantation Outcomes and Treatments (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). David Rageot is often cited by papers focused on Genetic factors in colorectal cancer (4 papers), Renal Transplantation Outcomes and Treatments (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). David Rageot collaborates with scholars based in France, Italy and Canada. David Rageot's co-authors include Laurent Martin, E Justrabo, F. Guignier, Christiane Mousson, Gérard Rifle, F Piard, Caroline Chapusot, Anne‐Marie Bouvier, Jean Faivre and Tibor Ponnelle and has published in prestigious journals such as Journal of Clinical Investigation, Scientific Reports and British Journal of Cancer.

In The Last Decade

David Rageot

16 papers receiving 392 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Rageot France 10 145 135 108 102 93 18 398
Joan Morote Spain 11 91 0.6× 114 0.8× 45 0.4× 69 0.7× 20 0.2× 22 489
S. Michelle Shiller United States 9 196 1.4× 75 0.6× 17 0.2× 219 2.1× 22 0.2× 15 433
Weiguo Sui China 7 45 0.3× 27 0.2× 74 0.7× 35 0.3× 11 0.1× 10 340
Francesco Lasorsa Italy 15 21 0.1× 151 1.1× 59 0.5× 118 1.2× 21 0.2× 45 881
Maria Vaysberg United States 8 10 0.1× 151 1.1× 85 0.8× 22 0.2× 86 0.9× 9 343
Jeroen Depreeuw Belgium 9 10 0.1× 116 0.9× 23 0.2× 29 0.3× 108 1.2× 13 491
Jérôme Alexandre France 3 10 0.1× 139 1.0× 22 0.2× 16 0.2× 57 0.6× 4 445
Claudio Losio Italy 10 28 0.2× 59 0.4× 5 0.0× 191 1.9× 21 0.2× 15 343
Lola Luo United States 8 6 0.0× 113 0.8× 61 0.6× 21 0.2× 22 0.2× 8 403
Nicola Antonio di Meo Italy 9 11 0.1× 82 0.6× 21 0.2× 60 0.6× 19 0.2× 11 498

Countries citing papers authored by David Rageot

Since Specialization
Citations

This map shows the geographic impact of David Rageot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Rageot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Rageot more than expected).

Fields of papers citing papers by David Rageot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Rageot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Rageot. The network helps show where David Rageot may publish in the future.

Co-authorship network of co-authors of David Rageot

This figure shows the co-authorship network connecting the top 25 collaborators of David Rageot. A scholar is included among the top collaborators of David Rageot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Rageot. David Rageot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Thibaudin, Marion, Antonin Schmitt, Leila Bengrine, et al.. (2025). Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial. Signal Transduction and Targeted Therapy. 10(1). 22–22. 1 indexed citations
2.
Galland, Loïck, Valentin Dérangère, David Rageot, et al.. (2025). Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. Journal of Clinical Investigation. 135(13). 3 indexed citations
3.
4.
5.
Rouland, Alexia, Thomas Gautier, Damien Denimal, et al.. (2024). The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes. Metabolites. 14(9). 487–487.
6.
Truntzer, Caroline, David Rageot, Françoise Beltjens, et al.. (2024). Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. Biomedicines. 12(12). 2754–2754. 1 indexed citations
7.
Dérangère, Valentin, David Rageot, Angélique Vienot, et al.. (2023). CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy. OncoImmunology. 13(1). 2294563–2294563. 1 indexed citations
8.
Berger, Hélène, Cédric Rébé, Elise Ballot, et al.. (2021). Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. Journal for ImmunoTherapy of Cancer. 9(6). e002157–e002157. 79 indexed citations
9.
Ballot, Elise, Caroline Truntzer, Valentin Dérangère, et al.. (2021). Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images. Scientific Reports. 11(1). 23912–23912. 18 indexed citations
10.
Rageot, David, et al.. (2019). A Multicentre Pilot Study of a Two-Tier Newborn Sickle Cell Disease Screening Procedure with a First Tier Based on a Fully Automated MALDI-TOF MS Platform. International Journal of Neonatal Screening. 5(1). 10–10. 9 indexed citations
11.
Perségol, L., Marie‐Claude Brindisi, David Rageot, et al.. (2014). Oxidation-induced loss of the ability of HDL to counteract the inhibitory effect of oxidized LDL on vasorelaxation. Heart and Vessels. 30(6). 845–849. 10 indexed citations
12.
Martin, Laurent, et al.. (2006). Expression of TGFβ-1 and Type I TGFβ-Receptor on Sequential Biopsies of Renal Transplants With Chronic Allograft Nephropathy. Transplantation Proceedings. 38(7). 2327–2329.
13.
Martin, Laurent, F. Guignier, Philippe d’Athis, et al.. (2005). Detection of Anti-HLA Antibodies with Flow Cytometry in Needle Core Biopsies of Renal Transplants Recipients with Chronic Allograft Nephropathy. Transplantation. 79(10). 1459–1461. 40 indexed citations
14.
Chapusot, Caroline, Laurent Martin, Pierre Laurent‐Puig, et al.. (2004). What Is the Best Way to Assess Microsatellite Instability Status in Colorectal Cancer?. The American Journal of Surgical Pathology. 28(12). 1553–1559. 35 indexed citations
15.
Ponnelle, Tibor, Caroline Chapusot, Laurent Martin, et al.. (2003). Subcellular Expression of c-IAP1 and c-IAP2 in Colorectal Cancers: Relationships with Clinicopathological Features and Prognosis. Pathology - Research and Practice. 199(11). 723–731. 24 indexed citations
16.
Martin, Laurent, F. Guignier, Christiane Mousson, et al.. (2003). Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy1. Transplantation. 76(2). 395–400. 112 indexed citations
17.
18.
Chapusot, Caroline, Laurent Martin, Anne‐Marie Bouvier, et al.. (2002). Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. British Journal of Cancer. 87(4). 400–404. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan Morote Breakdown of academic impact, for papers by S. Michelle Shiller Breakdown of academic impact, for papers by Weiguo Sui Breakdown of academic impact, for papers by Francesco Lasorsa Breakdown of academic impact, for papers by Maria Vaysberg Breakdown of academic impact, for papers by Jeroen Depreeuw Breakdown of academic impact, for papers by Jérôme Alexandre Breakdown of academic impact, for papers by Claudio Losio Breakdown of academic impact, for papers by Lola Luo Breakdown of academic impact, for papers by Nicola Antonio di Meo
Rankless by CCL
2026